When Maureen Sideris was treated for colon cancer in 2008, her recovery followed the traditional and often physically demanding path of surgery and post-operative rehabilitation. The treatment was successful, but the process was long and exhausting.

Fourteen years later, when the 71-year-old New York resident was diagnosed with oesophageal cancer, her treatment took a markedly different form. Instead of surgery, chemotherapy or radiation, she enrolled in a clinical trial at Memorial Sloan Kettering Cancer Center and began receiving infusions of the immunotherapy drug Dostarlimab every three weeks.

Each session lasted about 45 minutes. After four months, her tumour had disappeared.Sideris says the result felt almost unreal. Apart from adrenal insufficiency that causes fatigue, she experienced few major side effects. “It’s unbelievable,” she said. “It’s almost like science fiction.”Her case reflects a broader shift underway in oncology, where immunotherapy a treatment strategy designed to help the body’s own immune system recognize and destroy cancer cells is increasingly moving from experimental promise to routine clinical application.

After decades of research, oncologists say immunotherapy is now producing long-term remission and, in some cases, functional cures for patients who previously faced invasive surgery or limited treatment options.“I get choked up and have goosebumps,” said Jennifer Wargo, a professor of surgical oncology and immunotherapy researcher at MD Anderson Cancer Center.

“People are living, and living with good quality lives. We’re talking about cures.”The science behind immunotherapy is based on a relatively simple principle. The immune system is naturally designed to identify and eliminate cells that appear foreign or abnormal, including cells that become cancerous.

Karen Knudsen, chief executive of the Parker Institute for Cancer Immunotherapy, said the body is normally able to detect and remove cells that look like they do not belong. But cancer can evade that surveillance by making itself appear indistinguishable from surrounding healthy tissue.

Immunotherapy aims to reverse that concealment by helping the immune system identify cancer for what it is and launch a targeted response.Two of the most established forms of immunotherapy today are CAR T-cell therapy and immune checkpoint inhibitors.CAR T-cell therapy involves removing T cells the immune cells responsible for targeting specific threats from a patient’s blood, modifying them in a laboratory so they can better detect cancer, and then returning them to the body.

These therapies are currently used primarily for blood cancers.Immune checkpoint inhibitors work differently. They disable one of the immune system’s built-in “off switches,” mechanisms that normally prevent excessive immune responses from damaging healthy tissue.

Some cancer cells exploit these off switches, effectively telling immune cells not to attack. Checkpoint inhibitors prevent that signal, allowing T cells to identify tumours as threats and respond accordingly.

The significance of this approach was recognized globally when the scientists behind checkpoint inhibitor research were awarded the Nobel Prize in Physiology or Medicine 2018. These drugs are now used across multiple cancer types.However, both approaches have limitations.

Researchers have struggled to make CAR T-cell therapies consistently effective against solid tumours, which account for more than 90% of new cancer diagnoses. The treatment is also expensive and logistically complex because it requires individualized cell engineering.Checkpoint inhibitors can be easier to administer, but they carry risks.

Samra Turajlic, a medical oncologist at the Francis Crick Institute, described the side effects as a “kaleidoscope,” reflecting how broadly the immune system can react once normal regulatory controls are reduced.

Because these drugs remove safeguards meant to prevent the body from attacking itself, patients may experience immune-related complications involving healthy organs as well as tumours.

According to the National Cancer Institute, common side effects include fatigue, diarrhoea and skin rashes, while rare complications can involve inflammation of the liver, kidneys and heart.

Even when side effects are manageable, the larger problem is inconsistency.Turajlic said no immunotherapy works for all patients. Response depends on multiple factors, including the structure of the tumour, how accessible it is to immune cells, and the biological characteristics of the patient’s own immune system.

Current estimates suggest only 20% to 40% of patients respond meaningfully to immunotherapy, meaning many undergo treatment, side effects and emotional strain without clear benefit.That gap has pushed researchers toward combination strategies and more personalized approaches.Wargo’s early research suggests patients who follow high-fibre diets may improve treatment response through changes in the gut microbiome, which can influence both immune behavior and tumour biology.

Other studies indicate that statins, commonly prescribed cholesterol-lowering drugs, may unexpectedly enhance immunotherapy by altering cellular communication pathways.Timing may also matter. Some recent findings suggest patients treated earlier in the day may respond better than those receiving therapy later, raising new questions about how biological rhythms influence cancer care.

Combining immunotherapy with radiation or ultrasound is another area of active research.Sandra Demaria of Weill Cornell Medical Center said radiation can make tumours more visible to the immune system by changing how cancer cells present themselves. Ultrasound therapy, which uses high-frequency sound waves to target tumours, may have similar effects.

For many researchers, however, the most important shift is not simply adding more treatments, but identifying which patients are most likely to benefit from specific therapies.“We can now move toward treating not the cancer, but actually the patient,” Demaria said.Knudsen said that approach is especially important because cancer is not a single disease.

Oncology encompasses hundreds of biologically distinct conditions, and even patients with the same diagnosis may have profoundly different disease behavior at the cellular level.That principle is already shaping clinical practice at Memorial Sloan Kettering.

Researchers there identified that tumours carrying a specific genetic signature respond especially well to checkpoint inhibitors such as dostarlimab. In small clinical trials conducted in 2022 and 2024, patients with rectal cancers carrying that profile saw complete tumour eradication.

The institution later expanded the study to 117 patients with different cancers including oesophageal, bladder and stomach tumours that shared the same genetic marker.

Among the 103 patients who completed the full course of treatment, 84 experienced complete disappearance of their tumours. Only two required additional surgery.

Sideris was among those patients.

Her case illustrates how immunotherapy is changing expectations around cancer treatment. What once required major surgery can, for a growing subset of patients, now be addressed through carefully targeted immune intervention.Researchers caution that such outcomes remain highly dependent on tumour biology and patient selection, and they do not apply universally.

But the progress has changed how many oncologists view the future of cancer care less focused on destroying tumours through increasingly aggressive intervention, and more centered on teaching the body to do the work itself.

A 47-year-old woman with three severe autoimmune disorders has achieved sustained remission following treatment with an experimental cell therapy that reprograms the immune system, according to clinicians involved in her care.

The patient, who had lived with life-threatening autoimmune conditions for more than a decade, had undergone nine separate treatments without lasting success before receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, last year.

Since then, doctors report that she has remained free from treatment for 14 months and has returned to a near-normal daily routine.The procedure was conducted at University Hospital Erlangen, where clinicians described the patient’s response as both rapid and unprecedented across multiple autoimmune conditions.

At the time of treatment, the patient required daily blood transfusions and long-term anticoagulation therapy to manage complications arising from her illnesses.Professor Fabian Müller, who led the clinical team, said the patient’s improvement was both swift and significant.

He noted that the therapy had “significantly improved her quality of life,” while cautioning that further clinical trials would be required to determine how durable the response may be and whether similar outcomes could be replicated in other patients.

The woman had been diagnosed with Autoimmune haemolytic anaemia, a condition in which the immune system destroys red blood cells, often necessitating immunosuppressive therapy and repeated transfusions. In her case, standard treatments had ceased to be effective, leaving her dependent on continuous medical support.

According to Müller, she had effectively exhausted all available therapeutic options prior to receiving the experimental intervention.

In addition to AIHA, the patient suffered from Immune thrombocytopenia, a disorder that reduces platelet counts and increases the risk of bleeding, and Antiphospholipid syndrome, which conversely elevates the risk of blood clot formation.

All three conditions are driven by dysfunction in B-cells, a type of white blood cell responsible for producing antibodies.
CAR-T therapy, originally developed and widely used in certain blood cancers, involves extracting a patient’s T-cells and genetically modifying them to target specific proteins on harmful cells.

In this case, clinicians engineered the T-cells to recognise CD19, a protein found on B-cells. Once reintroduced into the patient’s body, the modified cells targeted and eliminated the malfunctioning B-cells responsible for the autoimmune response.

Doctors observed clinical improvement within weeks of administering the therapy. The patient required her final blood transfusion one week after treatment and regained sufficient strength to resume normal daily activities within two weeks.

Subsequent monitoring indicated that her immune system had ceased attacking red blood cells, while symptoms associated with her other autoimmune disorders also subsided.

When B-cells eventually re-emerged months later, clinicians reported that they appeared to function normally, suggesting a possible “reset” of the immune system. This observation has drawn attention from researchers studying autoimmune diseases, where long-term disease control remains a significant challenge.

Professor Ben Parker, a consultant rheumatologist at the Manchester University NHS Foundation Trust, said the case offered encouraging evidence that CAR-T therapy could address multiple autoimmune conditions simultaneously. He noted that the absence of relapse despite discontinuation of conventional therapies pointed to a fundamental change in immune system behaviour.

Parker, who is leading CAR-T clinical trials targeting autoimmune diseases, including lupus, said there is growing interest in expanding the therapy’s application beyond oncology. He added that multiple trials are currently underway or recruiting patients across a range of conditions, including systemic lupus erythematosus, myositis, multiple sclerosis, systemic sclerosis, and vasculitis.

Despite the promising outcome, clinicians emphasised the need for caution. The long-term safety and durability of CAR-T therapy in autoimmune diseases remain under investigation, and its broader use will depend on results from controlled clinical trials.

The findings from the patient’s case have been published in the peer-reviewed journal Med, providing detailed insights into the treatment protocol and clinical outcomes.

Researchers noted that while the patient continues to show mild abnormalities, including a reduced white blood cell count and slightly elevated liver enzymes, these are believed to be residual effects of prior treatments rather than consequences of the CAR-T intervention.

The case represents a potential shift in the treatment paradigm for autoimmune diseases, particularly for patients with severe, treatment-resistant conditions.

However, clinicians and researchers stress that further evidence is required before the therapy can be considered a standard treatment option beyond controlled clinical settings.

The U.S. Food and Drug Administration begins a new chapter in its drug evaluation and research division, focusing on ethics, transparency, and accelerated innovation in medical safety and approvals.

The U.S. Food and Drug Administration has announced a leadership transition within its Center for Drug Evaluation and Research.

This change marks a renewed focus on ethical governance, transparency, and the continued protection of public health across the nation.

The FDA remains a cornerstone of global drug safety and medical innovation.

With a commitment to upholding the highest professional and ethical standards, the agency’s leadership transition aims to enhance confidence in its policies and regulatory framework.

Officials reaffirmed their dedication to maintaining trust with the public, the medical community, and the pharmaceutical industry.

The Department of Health and Human Services emphasized that the change in leadership is part of its broader mission to ensure accountability and strengthen the FDA’s decision-making process.

By maintaining an environment of openness and collaboration, the FDA seeks to empower scientific teams to focus on evidence-based regulation.

The agency continues to oversee the approval and monitoring of over-the-counter and prescription medicines used by millions of Americans every day.

Industry experts say the leadership change offers an opportunity to refine the FDA’s innovative programs, including fast-track drug approvals and modernized testing standards.

These initiatives help bring critical treatments to patients faster while maintaining rigorous safety protocols.

The agency has also reaffirmed its commitment to transparency in communications and ensuring that every decision is rooted in solid scientific analysis.

Officials believe that this renewed emphasis on ethical leadership will help foster stronger relationships with healthcare providers and pharmaceutical innovators.

This transition comes at a time when global health agencies are undergoing modernization efforts to adapt to rapid scientific advances and the growing complexity of medical research.

The FDA is playing a crucial role in guiding this transformation by integrating advanced data analytics, artificial intelligence, and real-world evidence into its review processes.

The leadership reshuffle is expected to encourage smoother coordination among divisions, allowing for faster response times to emerging health challenges.

This includes addressing public health emergencies, approving breakthrough therapies, and ensuring access to affordable, high-quality medicines.

The agency also remains committed to collaboration with international health bodies to align regulatory standards and streamline global approvals.

Such cooperation strengthens confidence in the safety and effectiveness of U.S.-approved medical products worldwide.

Under the direction of Health Secretary Robert F. Kennedy Jr., the department has been actively working toward improving transparency and accountability across all U.S. health agencies.

These efforts are part of a larger vision to rebuild trust between health institutions and the public while encouraging innovation in life sciences.

Experts suggest that transitions like these can often energize an organization by bringing fresh perspectives and renewed focus to key priorities.

Stakeholders in the healthcare sector have welcomed the move as a step toward enhancing clarity, communication, and consistency within the regulatory ecosystem.

The FDA’s ability to balance innovation with public safety continues to make it one of the most respected institutions in the global health landscape.

With new leadership, the agency aims to strengthen its role as a protector of public well-being while embracing scientific progress that benefits future generations.

This new phase of leadership underscores a simple truth: the FDA’s mission remains unwavering — to ensure that every drug on the market meets the highest standards of safety, quality, and efficacy.

Through a culture of integrity, innovation, and transparency, the U.S. Food and Drug Administration is preparing to lead America’s healthcare system into a safer, more effective, and technologically advanced future.

This approval highlights the Kingdom’s commitment to advancing healthcare innovation and improving patient access to cutting-edge therapies.

The Saudi Food and Drug Authority (SFDA) has approved Qalsody (Tofersen), marking a major step forward in treating adults with ALS linked to SOD1 gene mutations and expanding access to life-changing therapies in the Kingdom.

ALS is a progressive neurodegenerative disease that targets nerve cells responsible for voluntary movement, gradually causing muscle weakness, loss of mobility, and significant impacts on daily life.

While the condition is rare, patients and families affected by SOD1-linked ALS face unique challenges due to the genetic mutation producing a defective SOD1 protein, which disrupts normal cellular processes by failing to eliminate toxic byproducts.

Qalsody represents a breakthrough in treating this rare condition through antisense therapy, a novel therapeutic approach that uses small nucleotide molecules designed to bind precisely to the mutated gene’s mRNA.

By targeting the defective SOD1 protein at its source, Qalsody helps reduce its production and accumulation in nerve cells, potentially slowing disease progression and providing new hope for patients.

The SFDA emphasized that the drug’s approval followed a thorough evaluation of its efficacy, safety, and quality. Clinical trials demonstrated that patients receiving Qalsody experienced reductions in critical indicators of nerve damage, including neurofilament light levels, compared with placebo-treated patients.

Additionally, the concentration of defective SOD1 protein in cerebrospinal fluid decreased, confirming that the drug effectively targets the disease’s molecular root. While long-term benefits are still being assessed, early findings indicate promising outcomes for adults living with SOD1-linked ALS.

In terms of safety, the most common side effects observed during clinical studies included muscle and joint pain, fatigue, injection site discomfort, fever, and elevated protein levels in cerebrospinal fluid, which were generally manageable.

The SFDA noted that ongoing monitoring will continue to ensure patient safety while maximizing therapeutic benefits.

The approval of Qalsody is part of the SFDA’s Orphan Drugs Program, a strategic initiative aimed at accelerating access to innovative therapies for rare and hard-to-treat diseases.

By facilitating the availability of these critical medications, the program addresses unmet medical needs and reinforces Saudi Arabia’s dedication to improving patient care for conditions affecting fewer than five in 10,000 people in the Kingdom.

Health experts hailed the move as a significant milestone in the Kingdom’s healthcare transformation. The approval aligns with the Health Sector Transformation Program, one of the key pillars of Vision 2030, which seeks to enhance the quality and accessibility of healthcare services nationwide.

By integrating advanced therapies such as Qalsody into clinical practice, Saudi Arabia continues to position itself as a regional leader in medical innovation and rare disease treatment.

“This is a major advancement for patients living with ALS in the Kingdom,” said an SFDA spokesperson. “The approval of Qalsody reflects our ongoing commitment to facilitating access to safe and effective treatments, particularly for rare diseases where options have been limited.”

Patient advocacy groups also welcomed the approval, noting that it brings renewed hope to families grappling with the challenges of ALS.

The introduction of targeted therapies such as Qalsody underscores the importance of investing in cutting-edge science and fostering collaboration between regulators, healthcare providers, and pharmaceutical innovators.

With Qalsody now registered in Saudi Arabia, patients with SOD1-linked ALS have access to a therapy that not only addresses the underlying genetic cause of their disease but also represents the Kingdom’s broader ambition to enhance healthcare quality, innovation, and accessibility in line with Vision 2030 goals.

The SFDA’s approval marks a historic step forward, emphasizing both scientific progress and the Kingdom’s patient-centered approach to healthcare.

Qalsody’s entry into the Saudi market highlights a new era of hope for adults living with ALS and reinforces the nation’s position at the forefront of rare disease treatment in the Middle East.

Orforglipron is part of a new class of GLP-1 drugs that suppress appetite and follow the same pathway targeted by Eli Lilly’s blockbuster tirzepatide, sold globally as the blockbuster Mounjaro for diabetes and Zepbound for weight loss.

The drug has not been launched anywhere globally but Lilly plans to file,for approval of orforglipron with regulators in the United States, Britain, European Union, Japan and China.

It was not immediately clear if the drugmaker has started approval procedure for orforglipron in India.

Latest trial data showed Eli Lilly’s experimental pill orforglipron lowered blood sugar and weight more effectively than Novo Nordisk’s (NOVOb.CO), older GLP-1 drug Rybelsus in adults with type-2 diabetes.

“There is promise for products like that in India, if it gets approved,” Winselow Tucker, Lilly India’s president, said, speaking at an industry conference panel in Mumbai. He did not give a launch timeline.

People in India would take their tablets rather than inject, Novo Nordisk India head Vikrant Shrotriya said.

Tucker added that stigma and logistical hurdles also weigh on injectables.

Still, both companies remain upbeat on the market. Novo’s Wegovy and Lilly’s Mounjaro, launched earlier this year, have seen demand surge, with sales doubling within months.

“We are seeing growing acceptance of obesity injectables in India,” Shrotriya said.